(+/-)-α-hydroxy-4-(trifluoromethyl)propiophenone | 158558-35-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (+/-)-α-hydroxy-4-(trifluoromethyl)propiophenone
• 英文别名: 2-hydroxy-1-(4-(trifluoromethyl)phenyl)propan-1-one；1-p-trifluoromethylphenyl-2-hydroxypropan-1-one；1-Propanone, 2-hydroxy-1-[4-(trifluoromethyl)phenyl]-；2-hydroxy-1-[4-(trifluoromethyl)phenyl]propan-1-one
• CAS: 158558-35-1
• 化学式: C₁₀H₉F₃O₂
• 分子量: 218.175
• InChiKey: SRSKNTMIVINURP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (+/-)-α-hydroxy-4-(trifluoromethyl)propiophenone 在 palladium on activated charcoal 吡啶 、 sodium azide 、 potassium tert-butylate 、 氢气 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 氯化铵 、 对甲苯磺酸 、 二甲基亚砜 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 25.0~115.0 ℃ 、101.33 kPa 条件下， 反应 48.0h， 生成 (2R,3R)-3-amino-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]butan-2-ol
  参考文献：
  名称：

  Synthesis and Antifungal Activity of New Azole Derivatives Containing an N-Acylmorpholine Ring

  摘要：

  A series of azole derivatives carrying an N-acylmorpholine ring are described. The compounds were chemically designed to simulate the lanosterol D ring, taking advantage of the conformational preferences of 2-alkyl-1-acylmorpholines. Three structural variables, the nature of the N-benzoyl group, the phenyl substituents, and the degree of oxidation at carbon 2 of the morpholine, were optimized for maximum activity. Only the (5R,6R) isomers showed antifungal activity. Cyclic hemiacetal(-)-39a (UR-9746) and cyclic ether (-)-41 (UR-9751) were selected for further development. In vitro, (-)-41 was clearly more active than (-)-39a and somewhat less active than the acyclic counterpart (-)-7. lit vivo activity was assessed by a systemic (mouse) and a vaginal (rat) candidosis model. In the former, (-)-39a, (-)-41, and (-)-7 at 1 mg/kg given 1, 4, and 24 h postinfection displayed 90-100% protection from mortality on day 9. Compound (-)-39a was slightly more potent than (-)-41 and similar in potency to (-)-7. The three compounds were superior in potency to fluconazole and similar in potency to SCH-42427 in this test. In the vaginal model, (-)-39a and (-)-41 given daily during 3 days after infection at 0.5 mg/kg showed high levels of protection on days 10 and 15. At 0.25 mg/kg, (-)-39a was slightly more potent than SCH-42427 and (-)-7 and superior in potency to (-)-41 and fluconazole in this model. Preliminary 28-day toxicity tests at 100 mg/kg/day po in rats indicated no or very mild adverse effects for the two UR compounds.

  DOI：

  10.1021/jm00020a005
• 作为产物：
  描述：

  2-溴-1-(4-(三氟甲基)苯基)-1-丙酮 在 lithium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以67%的产率得到(+/-)-α-hydroxy-4-(trifluoromethyl)propiophenone
  参考文献：
  名称：

  Synthesis and Antifungal Activity of New Azole Derivatives Containing an N-Acylmorpholine Ring

  摘要：

  A series of azole derivatives carrying an N-acylmorpholine ring are described. The compounds were chemically designed to simulate the lanosterol D ring, taking advantage of the conformational preferences of 2-alkyl-1-acylmorpholines. Three structural variables, the nature of the N-benzoyl group, the phenyl substituents, and the degree of oxidation at carbon 2 of the morpholine, were optimized for maximum activity. Only the (5R,6R) isomers showed antifungal activity. Cyclic hemiacetal(-)-39a (UR-9746) and cyclic ether (-)-41 (UR-9751) were selected for further development. In vitro, (-)-41 was clearly more active than (-)-39a and somewhat less active than the acyclic counterpart (-)-7. lit vivo activity was assessed by a systemic (mouse) and a vaginal (rat) candidosis model. In the former, (-)-39a, (-)-41, and (-)-7 at 1 mg/kg given 1, 4, and 24 h postinfection displayed 90-100% protection from mortality on day 9. Compound (-)-39a was slightly more potent than (-)-41 and similar in potency to (-)-7. The three compounds were superior in potency to fluconazole and similar in potency to SCH-42427 in this test. In the vaginal model, (-)-39a and (-)-41 given daily during 3 days after infection at 0.5 mg/kg showed high levels of protection on days 10 and 15. At 0.25 mg/kg, (-)-39a was slightly more potent than SCH-42427 and (-)-7 and superior in potency to (-)-41 and fluconazole in this model. Preliminary 28-day toxicity tests at 100 mg/kg/day po in rats indicated no or very mild adverse effects for the two UR compounds.

  DOI：

  10.1021/jm00020a005

文献信息

• 一种α-羟基酮的绿色制备方法
  申请人：西北师范大学

  公开号：CN108083999B

  公开（公告）日：2020-08-11

  本发明涉及一种α‑羟基酮的绿色制备方法，该方法是指依次将酮、碘、1,4‑二氮杂二环[2.2.2]辛烷、甲醇加入到玻璃反应瓶中；然后在23 W紧凑型荧光灯照射下，于空气氛中室温搅拌反应14~30 h，得到反应混合物，该反应混合物经硅胶柱色谱分离即得纯的α‑羟基酮。本发明具有绿色、高效、操作简单、条件温和、适用广泛、易工业化的特点。
• Base-Promoted Three-Component Cascade Reaction of α-Hydroxy Ketones, Malonodinitrile, and Alcohols: Direct Access to Tetrasubstituted N<i>H</i>-Pyrroles
  作者：Hongjian Liu、Chaorong Qi、Lu Wang、Yanhui Guo、Dan Li、Huanfeng Jiang

  DOI：10.1021/acs.joc.1c00882

  日期：2021.7.16

  malonodinitrile, and alcohols has been developed, providing a direct and efficient route to a range of structurally diverse and synthetically useful 2-alkyloxy-1H-pyrrole-3-carbonitrile derivatives. The reaction involved three different bond (C–C, C–O, and C–N) formations in a single step, and its regioselectivity was depended on the structure of the α-hydroxy ketones employed. The use of easily available

  已经开发了 α-羟基酮、丙二腈和醇的碱促进三组分级联反应，为一系列结构多样且合成有用的 2-烷氧基-1 H-吡咯-3-腈提供了直接有效的途径衍生品。该反应在一个步骤中涉及三种不同的键（C-C、C-O 和 C-N）的形成，其区域选择性取决于所使用的 α-羟基酮的结构。使用容易获得的起始材料、广泛的底物范围、良好的官能团耐受性、操作简单和高原子经济性是新方法的吸引人的特点。
• Halogen-bonded iodonium ion catalysis: a route to α-hydroxy ketones via domino oxidations of secondary alcohols and aliphatic C–H bonds with high selectivity and control
  作者：Somraj Guha、Imran Kazi、Pranamita Mukherjee、Govindasamy Sekar

  DOI：10.1039/c7cc05697d

  日期：——

  been developed from benzylic secondary alcohols employing catalytic iodonium ions stabilized by DMSO. The reaction proceeds through an unprecedented sequential oxidation of alcohols to ketone and its α-hydroxylation in a controlled manner. The spectroscopic evidences establish the possibility of formation of a stable halogen–bonded adduct between DMSO and iodonium ions.

  由苄基仲醇开发了α-羟基酮的多米诺合成，该苄基仲醇采用了由DMSO稳定的催化碘鎓离子。该反应通过将醇以前所未有的顺序氧化成酮并以受控方式进行其α-羟基化而进行。光谱学证据确定了在DMSO和碘鎓离子之间形成稳定的卤素键合加合物的可能性。
• DBU-Promoted Dynamic Kinetic Resolution in Rh-Catalyzed Asymmetric Transfer Hydrogenation of 5-Alkyl Cyclic Sulfamidate Imines: Stereoselective Synthesis of Functionalized 1,2-Amino Alcohols
  作者：Hyeong Rae Kim、Raghavendra Achary、Hyeon-Kyu Lee

  DOI：10.1021/acs.joc.8b01892

  日期：2018.10.5

  Dynamic kinetic resolution (DKR)-driven asymmetric transfer hydrogenation of 5-alkyl cyclic sulfamidate imine produces the corresponding sulfamidate with excellent levels of diastereo- and enantioselectivity by employing a HCO2H/DBU mixture as the hydrogen source in the presence of the Noyori-type chiral Rh-catalyst at room temperature for 1 h. In this process, DKR was induced by DBU-promoted rapid

  通过动态动力学拆分（DKR）驱动的5-烷基环氨基磺酸亚胺的不对称转移氢化反应，通过在Noyori-存在下使用HCO 2 H / DBU混合物作为氢源，产生具有极佳非对映选择性和对映选择性的相应氨基磺酸盐型手性Rh催化剂在室温下放置1 h。在此过程中，DKR是由DBU促进的底物快速消旋作用诱导的。还描述了所得环状氨基磺酸盐向官能化对映体富集的1，2-氨基醇和手性胺物质的立体选择性转化。
• Orally active azole derivatives
  申请人：J. Uriach & Cia. S.A.

  公开号：US05478826A1

  公开（公告）日：1995-12-26

  The present invention relates to new orally active azole derivatives with antifungal activity of formula I ##STR1## wherein: X is CH or N; Ar represents phenyl substituted with halogen and/or trifluoromethyl; Z is --C(=O)-- or --SO.sub.2 --; R.sub.1 is CN, CO.sub.2 H, CO.sub.2 R.sub.7, CONR.sub.8 R.sub.9 or CH.sub.2 Y and then R.sub.3 is hydrogen, or R.sub.1 together with R.sub.3 forms a ring of formula I' ##STR2## wherein B is O, hydroxy or hydrogen; R.sub.4 is C.sub.1-4 alkyl; R.sub.5, R.sub.6, R.sub.8 and R.sub.9 are hydrogen or C.sub.1-4 alkyl; Y is --OH, --OR.sub.7, --OC(=O)R.sub.7, --NR.sub.8 R.sub.9, --NHC(=O)OR.sub.7 ; R.sub.7 is C.sub.1 -C.sub.4 -alkyl, phenyl-C.sub.1 -C.sub.4 -alkyl or optionally substituted phenyl; when Z is --C(=O)--, R.sub.2 is optionally susbtituted phenyl, or naphtyl; when Z is --SO.sub.2 --, R.sub.2 is C.sub.1-4 alkyl, phenyl-C.sub.1-4 -alkyl or optionally susbtituted phenyl.

  本发明涉及具有抗真菌活性的新口服活性唑类衍生物，其化学式为I 其中：X为CH或N；Ar代表用卤素和/或三氟甲基取代的苯基；Z为--C(=O)--或--SO.sub.2--；R.sub.1为CN、CO.sub.2 H、CO.sub.2 R.sub.7、CONR.sub.8 R.sub.9或CH.sub.2Y，然后R.sub.3为氢，或R.sub.1与R.sub.3一起形成化学式I'的环 其中B为O、羟基或氢；R.sub.4为C.sub.1-4烷基；R.sub.5、R.sub.6、R.sub.8和R.sub.9为氢或C.sub.1-4烷基；Y为--OH、--OR.sub.7、--OC(=O)R.sub.7、--NR.sub.8 R.sub.9、--NHC(=O)OR.sub.7；R.sub.7为C.sub.1-C.sub.4-烷基、苯基-C.sub.1-C.sub.4-烷基或可选择取代的苯基；当Z为--C(=O)--时，R.sub.2为可选择取代的苯基或萘基；当Z为--SO.sub.2--时，R.sub.2为C.sub.1-4烷基、苯基-C.sub.1-4-烷基或可选择取代的苯基。